导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.49% | 53/147 |
| 近一周 | -2.23% | 46/153 |
| 近一月 | -1.57% | 44/153 |
| 近一季 | 0.58% | 39/153 |
| 近半年 | -5.09% | 51/149 |
| 近一年 | -10.00% | 28/144 |
| 近两年 | 36.78% | 48/119 |
| 近三年 | 33.34% | 22/89 |
| 成立以来 | 51.91% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.21% 133/360 |
-8.08% 249/366 |
- - |
- - |
| 2025 | 25.66% 66/358 |
14.53% 103/340 |
3.78% 200/348 |
11.46% 132/354 |
-5.15% 210/358 |
| 2024 | 22.00% 79/329 |
-2.73% 194/280 |
8.64% 39/310 |
18.41% 91/318 |
-2.51% 184/329 |
| 2023 | -11.05% 167/275 |
0.75% 143/205 |
-1.91% 133/230 |
-7.29% 198/262 |
-2.91% 208/276 |
| 2022 | -7.79% 32/201 |
-6.99% 48/153 |
4.94% 58/164 |
-15.75% 101/189 |
12.13% 82/202 |
| 2021 | -14.76% 75/150 |
4.24% 85/312 |
0.74% 210/328 |
-13.45% 250/358 |
-6.21% 84/151 |
| 2020 | -7.05% 62/103 |
-13.59% 173/280 |
3.86% 239/295 |
-6.40% 273/299 |
10.64% 112/305 |
| 2019 | 12.24% 62/88 |
9.44% 136/258 |
1.86% 116/268 |
-5.75% 231/253 |
6.84% 122/266 |
| 2018 | -8.93% 44/79 |
- - |
- - |
- - |
-7.16% 84/241 |
| 2017 | 28.64% 13/69 |
- - |
- - |
- - |
- - |
| 2016 | 10.54% 17/59 |
- - |
- - |
- - |
- - |
| 2015 | 1.03% 20/49 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 广发中证香港创新药ETF(QDII) | 1.2744 | 27.49% |
| 广发道琼斯石油指数人民币A | 3.2498 | 26.68% |
| 广发道琼斯石油指数人民币C | 3.1927 | 26.58% |
| 广发道琼斯石油指数(QDII-LOF)人民币E | 3.2003 | 26.55% |
| 广发中证香港创新药ETF发起式联接(QDII)C | 1.3286 | 26.01% |
| 富国标普石油天然气勘探及生产精选行业ETF(QDII) | 1.4105 | 25.68% |
| 汇添富恒生生物科技ETF(QDII) | 1.1055 | 25.31% |
| 南方恒生生物科技ETF(QDII) | 1.1206 | 25.14% |
| 华宝标普油气上游股票美元A | 0.1538 | 24.94% |
| 广发中证香港创新药ETF发起式联接(QDII)A | 1.3401 | 24.24% |
| 华夏恒生ETF联接A VS. 建信富时100指数(QDII)人民币A(539003) |